Literature DB >> 9194952

The diagnostic value of magnetic resonance imaging and technetium 99m-HMPAO single-photon-emission computed tomography for the diagnosis of Alzheimer disease in a community-dwelling elderly population.

P Scheltens1, L J Launer, F Barkhof, H C Weinstein, C Jonker.   

Abstract

The objective of this study was to assess the diagnostic value for Alzheimer disease (AD) of single-photon-emission computed tomography (SPECT) and magnetic resonance imaging (MRI), separately and in combination. The study was part of a two-stage population-based study of mental functioning among noninstitutionalized 65-to 85-year-olds living in Amsterdam, The Netherlands. Participants (n = 51) were randomly selected within strata of cognitive function to obtain a sample of AD patients (n = 10) and clinically normal subjects (n = 41), of whom 22 displayed some cognitive impairment and fulfilled criteria for "minimal dementia" according to the Cambridge Examination for Mental Disorders of the Elderly. Coronal T1-weighted MRI was used to visualize the medial temporal lobe. Medial temporal lobe atrophy (MTA) was assessed qualitatively on a 0-4 scale. Regional cerebral blood flow on SPECT was assessed with the use of technetium 99m-HMPAO in three manually drawn regions of interest (frontal, parietal, and temporoparietal). Ratios were calculated by using the cerebellum as the reference area. MTA differed significantly between AD patients and clinically normal subjects (p = 0.0009), with sensitivity for AD of 70% and a specificity of 76%. None of the three SPECT ratios differed between normal and AD subjects. The temporoparietal/cerebellar ratio had a sensitivity of 30% and a specificity of 71% as a cutoff of 0.76. When both tests were positive the combined sensitivity was low (20%), but the false-positive rate was also very low (5%). A negative result on MRI or any SPECT ratio yielded a high specificity (93%-98%) but also a high false-negative rate (60-80%). Adding SPECT to MRI seems useful only if a diagnosis of AD is suspected clinically and confirmation is needed. When the clinical probability that AD is absent is high, normal results on either MRI or SPECT may confirm this notion. Given the fact that structural imaging should be performed in a clinical workup for dementia, using MRI only would be the most cost-effective approach.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9194952     DOI: 10.1097/00002093-199706000-00002

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  10 in total

1.  Predicting memory performance in normal ageing using different measures of hippocampal size.

Authors:  T C Lye; D A Grayson; H Creasey; O Piguet; H P Bennett; L J Ridley; J J Kril; G A Broe
Journal:  Neuroradiology       Date:  2005-12-20       Impact factor: 2.804

Review 2.  Molecular neuroimaging in Alzheimer's disease.

Authors:  William Jagust
Journal:  NeuroRx       Date:  2004-04

3.  Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation.

Authors:  W Staffen; U Schönauer; H Zauner; I Spindler; A Mair; B Iglseder; G Bernroider; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

4.  Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study.

Authors:  L O Wahlund; P Julin; S E Johansson; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-11       Impact factor: 10.154

Review 5.  Magnetic resonance imaging of Alzheimer's disease.

Authors:  Stéphane Lehéricy; Malgorzata Marjanska; Lilia Mesrob; Marie Sarazin; Serge Kinkingnehun
Journal:  Eur Radiol       Date:  2006-07-25       Impact factor: 5.315

Review 6.  The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2014-02-01

7.  The effect of age on cognitive performance of frontal patients.

Authors:  Lisa Cipolotti; Colm Healy; Edgar Chan; Sarah E MacPherson; Mark White; Katherine Woollett; Martha Turner; Gail Robinson; Barbara Spanò; Marco Bozzali; Tim Shallice
Journal:  Neuropsychologia       Date:  2015-06-20       Impact factor: 3.139

8.  Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms.

Authors:  Yvonne Höller; Arne C Bathke; Andreas Uhl; Nicolas Strobl; Adelheid Lang; Jürgen Bergmann; Raffaele Nardone; Fabio Rossini; Harald Zauner; Margarita Kirschner; Amirhossein Jahanbekam; Eugen Trinka; Wolfgang Staffen
Journal:  Front Aging Neurosci       Date:  2017-09-07       Impact factor: 5.750

9.  Diagnosis of Alzheimer's Disease in Developed and Developing Countries: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy.

Authors:  Miguel A Chávez-Fumagalli; Pallavi Shrivastava; Jorge A Aguilar-Pineda; Rita Nieto-Montesinos; Gonzalo Davila Del-Carpio; Antero Peralta-Mestas; Claudia Caracela-Zeballos; Guillermo Valdez-Lazo; Victor Fernandez-Macedo; Alejandro Pino-Figueroa; Karin J Vera-Lopez; Christian L Lino Cardenas
Journal:  J Alzheimers Dis Rep       Date:  2021-01-11

Review 10.  Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC.

Authors:  G B Frisoni; P h Scheltens; S Galluzzi; F M Nobili; N C Fox; P H Robert; H Soininen; L-O Wahlund; G Waldemar; E Salmon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.